LT2961426T - Centrinės nervų sistemos susirgimų gydymas, per nosį įvedant imunoglobuliną g - Google Patents

Centrinės nervų sistemos susirgimų gydymas, per nosį įvedant imunoglobuliną g

Info

Publication number
LT2961426T
LT2961426T LTEP14714815.9T LT14714815T LT2961426T LT 2961426 T LT2961426 T LT 2961426T LT 14714815 T LT14714815 T LT 14714815T LT 2961426 T LT2961426 T LT 2961426T
Authority
LT
Lithuania
Prior art keywords
immunoglobulin
treatment
central nervous
nervous diseases
diseases
Prior art date
Application number
LTEP14714815.9T
Other languages
English (en)
Lithuanian (lt)
Inventor
William Frey
Leah Ranae HANSON
Sharon Pokropinski
Francisco RAUSA
Original Assignee
Baxalta GmbH
Baxalta Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Incorporated filed Critical Baxalta GmbH
Publication of LT2961426T publication Critical patent/LT2961426T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
LTEP14714815.9T 2013-02-26 2014-02-25 Centrinės nervų sistemos susirgimų gydymas, per nosį įvedant imunoglobuliną g LT2961426T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361769673P 2013-02-26 2013-02-26
US201361862814P 2013-08-06 2013-08-06
PCT/US2014/018426 WO2014134070A1 (en) 2013-02-26 2014-02-25 Treatment of central nervous system disorders by intranasal administration of immunoglobulin g

Publications (1)

Publication Number Publication Date
LT2961426T true LT2961426T (lt) 2019-12-27

Family

ID=50424697

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14714815.9T LT2961426T (lt) 2013-02-26 2014-02-25 Centrinės nervų sistemos susirgimų gydymas, per nosį įvedant imunoglobuliną g

Country Status (13)

Country Link
US (5) US9556260B2 (enExample)
EP (2) EP2961426B1 (enExample)
JP (1) JP6379113B2 (enExample)
AU (2) AU2014223679B2 (enExample)
DK (1) DK2961426T3 (enExample)
ES (1) ES2759226T3 (enExample)
HR (1) HRP20192111T1 (enExample)
HU (1) HUE046752T2 (enExample)
LT (1) LT2961426T (enExample)
PL (1) PL2961426T3 (enExample)
PT (1) PT2961426T (enExample)
SI (1) SI2961426T1 (enExample)
WO (1) WO2014134070A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150100042A1 (en) * 2013-10-07 2015-04-09 Impel Neuropharma Inc. Muroid Family Nasal Device
EP3129013A1 (en) * 2014-04-10 2017-02-15 Crowley, Patrick Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CN110996912A (zh) 2017-08-20 2020-04-10 福摩莱克斯医药创新有限公司 用于鼻内递送的干粉组合物
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
WO2020163815A1 (en) * 2019-02-07 2020-08-13 Innomed Technologies, Inc. Ivig treatments for bell's palsy
WO2020263484A1 (en) * 2019-06-28 2020-12-30 Mayo Foundation For Medical Education And Research Methods and materials for treating neuromyelitis optica spectrum diseases
EP4021409A2 (en) * 2019-08-13 2022-07-06 Altimmune Inc Therapeutic agent effectiveness and its route of administration
US11400045B2 (en) 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
EP3991573A1 (de) * 2020-11-03 2022-05-04 Patrick Faber Zusammensetzungen zur nasalen applikation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (enExample) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
AU693306B2 (en) 1995-01-23 1998-06-25 Direct-Haler A/S An inhaler
NZ514442A (en) 1999-03-03 2003-08-29 Optinose As Nasal delivery device
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
US20070254889A1 (en) * 2001-04-23 2007-11-01 Lee-Way Jin Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease
WO2003028668A2 (en) 2001-10-04 2003-04-10 Protein Therapeutics, Inc. Gammaglobulin treatment of immune disorders
US20040101909A1 (en) 2002-08-20 2004-05-27 Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 Purification of polyreactive autoantibodies and uses thereof
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
MX2007010244A (es) 2005-02-23 2008-03-10 Johnson & Johnson Administracion intranasal de agentes activos al sistema nervioso central.
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
US8852585B2 (en) * 2006-01-30 2014-10-07 Grifols Therapeutics Inc. Method of treatment and prophylaxis of diseases related to amyloid deposition using IgM
MX2008010612A (es) * 2006-02-15 2009-03-20 Ramot At Tel Aviv University Bacteriofago filamentoso que exhibe proteina a como aglutinante de anticuerpos e inmunocomplejos para el suministro hacia el cerebro.
EP2152240A4 (en) 2007-06-08 2012-05-09 Healthpartners Res Foundation PHARMACEUTICAL COMPOSITIONS AND METHOD FOR REINFORCED TARGETING OF THERAPEUTIC COMPOUNDS TO THE CENTRAL NERVOUS SYSTEM
US8852874B2 (en) * 2008-02-29 2014-10-07 Baxter International Inc. Anti-amyloid β activity of intravenous immunoglobulin (IVIG) in vitro
US8622993B2 (en) 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
DK2531218T3 (en) 2010-02-04 2019-04-01 Csl Behring Ag immunoglobulin
US8772462B2 (en) * 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide

Also Published As

Publication number Publication date
ES2759226T3 (es) 2020-05-08
US10144776B2 (en) 2018-12-04
US12503501B2 (en) 2025-12-23
HRP20192111T1 (hr) 2020-03-20
JP2016512490A (ja) 2016-04-28
AU2018260883B2 (en) 2020-08-06
US9556260B2 (en) 2017-01-31
EP3597220A1 (en) 2020-01-22
US20140242067A1 (en) 2014-08-28
US20240117025A1 (en) 2024-04-11
US20190055307A1 (en) 2019-02-21
DK2961426T3 (da) 2019-12-02
EP2961426B1 (en) 2019-10-30
SI2961426T1 (sl) 2020-01-31
PT2961426T (pt) 2019-12-09
WO2014134070A1 (en) 2014-09-04
PL2961426T3 (pl) 2020-02-28
AU2014223679B2 (en) 2018-11-29
EP2961426A1 (en) 2016-01-06
HUE046752T2 (hu) 2020-03-30
US20170044244A1 (en) 2017-02-16
US11851481B2 (en) 2023-12-26
US20210101967A1 (en) 2021-04-08
JP6379113B2 (ja) 2018-08-22
AU2014223679A1 (en) 2015-09-24
AU2018260883A1 (en) 2018-11-29

Similar Documents

Publication Publication Date Title
IL268987B (en) System for glaucoma treatment
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
HUE061618T2 (hu) Vegyület szemrendellenességek kezelésére
LT3010910T (lt) Pirimidindiono junginiai, skirti širdies ligoms
LT3556775T (lt) Anti-lag-3 antikūnai, skirti hematologinių piktybinių susirgimų gydymui
DK3110843T3 (da) Kombinationsterapier med anti-cd38-antistoffer
HRP20181679T1 (hr) Amidni spojevi za liječenje hiv
LT2981255T (lt) Empagliflozino terapiniai panaudojimo būdai
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
DK3311824T3 (da) Cd47 målrettede terapier til behandlingen af infektionssygdomme
LT2885010T (lt) Tautopatijos gydymo būdai
LT2887944T (lt) Alopregnanolonas, skirtas atsparios epileptinės būklės gydymui
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
PT3626270T (pt) Tratamento de doenças cardiovasculares
PL2961426T3 (pl) Leczenie zaburzeń ośrodkowego układu nerwowego przez donosowe podawanie immunoglobuliny g
DK3244965T3 (da) Behandling af hovedpine med elektrisk stimulering
DK3065818T3 (da) Anordning til behandling af sygdomme i centralnervesystemet ved hjælp af sansestimulering
LT3007726T (lt) Tautopatijos gydymo būdai
LT3292875T (lt) Kompozicijos ir būdai, skirti ligų gydymui
LT2994160T (lt) Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
HUE056968T2 (hu) Bakteriofág terápia
HUS2000037I1 (hu) Triazinok Protozoa okozta betegségek kezelésére
IL254825A0 (en) Methods of treatment with taselisib
IL242220A0 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias